Therapeutic antibodies that cause aggressive tumors to become susceptible to treatment are being studied with the hope of one day changing the fate of patients who either relapse soon after cancer therapy or whose stubborn ...
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely ...
Aug 17, 2023
0
38
Immune checkpoint inhibitor (ICI) therapies used to treat cancer come with the risk of adverse autoimmune responses, including arthritis that can persist for years and require joint replacement surgery. Little is known about ...
Aug 1, 2023
0
74
Immune checkpoint inhibitor (ICI) therapy is a type of treatment for melanoma, the deadliest form of skin cancer, which blocks proteins on tumor or immune cells that prevent the immune system from killing cancer cells.
Sep 19, 2022
0
1486
Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes. Now, researchers from Osaka University have discovered that stem cell therapy may ...
May 5, 2022
0
139
Meningiomas, tumors of the membranes (meninges) surrounding the brain and spinal cord, are the most common tumors of the central nervous system. Although most meningiomas are low grade and cause few or no symptoms, a subset, ...
Mar 23, 2022
0
134
A new preclinical study led by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that treating people who have aggressive cancers, including melanoma, pancreatic and colorectal cancers, with immune checkpoint ...
Aug 19, 2021
0
353
A new cancer vaccine could boost the positive effects of existing immunotherapy drugs, improving the success rate of treatments from 20% to 75% of cases, according to a new study by immunologists from the University of Konstanz. ...
May 18, 2021
0
218
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently ...
Jul 8, 2020
0
113
University of Hawaiʻi Cancer Center researchers have conducted a phase II clinical trial investigating the potential of pembrolizumab maintenance therapy, a type of immunotherapy, in aggressive forms of breast cancer. The ...
Apr 18, 2024
0
9
